Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
M. Colombo(University of Milan), Heiner Wedemeyer(Medizinische Hochschule Hannover), A. Verheyen(Janssen (Belgium)), Adrian Streinu‐Cercel(Carol Davila University of Medicine and Pharmacy), Christophe Moreno(Genfit (France)), Petr Urbánek(Charles University), Isabelle Lonjon‐Domanec(Janssen (Belgium)), Wafae Iraqi(Janssen (Belgium)), Simone I. Strasser(University of Padua), J.M. Läuffer(Janssen (Switzerland)), Inmaculada Fernández(Hospital Universitario 12 De Octubre), Andrew Hill(Janssen (Belgium)), Ralph DeMasi(Janssen (Belgium)), Dzhamal Abdurakhmanov(Sechenov University), Paulo Roberto Abrão Ferreira(Universidade Federal de São Paulo)
Cited by 46
Related Papers
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653